Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma.

导出 OA

翻译打印收藏纠错

作者： Junjie,Zhao ^[1] ; Yanfeng,Tang ^[1] ; Xu,Hu ^[1] ; Xiaoxue,Yin ^[2] ; Yuntian,Chen ^[3] ; Junru,Chen ^[1] ; Haoyang,Liu ^[1] ; Haolin,Liu ^[1] ; Jiayu,Liang ^[1] ; Xingming,Zhang ^[1] ; Jinge,Zhao ^[1] ; Sha,Zhu ^[1] ; Yuchao,Ni ^[1] ; Zhipeng,Wang ^[1] ; Jindong,Dai ^[1] ; Zilin,Wang ^[1] ; Yaowen,Zhang ^[1] ; Jin,Yao ^[3] ; Ni,Chen ^[2] ; Pengfei,Shen ^[1] ; Zhenhua H,Liu ^[4] ; Hao,Zeng ^[5] ; Guangxi X,Sun ^[6]

作者单位： Department of Urology, Institute of Urology, Sichuan Clinical Research Center for kidney and urologic diseases, West China Hospital, Sichuan University, No.37 Guoxue Alley, Wuhou District, Chengdu, Sichuan Province, China. ^[1] Department of Pathology, West China Hospital, Sichuan University, Chengdu, China. ^[2] Department of Radiology, West China Hospital, Sichuan University, Chengdu, China. ^[3] Department of Urology, Institute of Urology, Sichuan Clinical Research Center for kidney and urologic diseases, West China Hospital, Sichuan University, No.37 Guoxue Alley, Wuhou District, Chengdu, Sichuan Province, China. zhliu@scu.edu.cn. ^[4] Department of Urology, Institute of Urology, Sichuan Clinical Research Center for kidney and urologic diseases, West China Hospital, Sichuan University, No.37 Guoxue Alley, Wuhou District, Chengdu, Sichuan Province, China. kucaizeng@163.com. ^[5] Department of Urology, Institute of Urology, Sichuan Clinical Research Center for kidney and urologic diseases, West China Hospital, Sichuan University, No.37 Guoxue Alley, Wuhou District, Chengdu, Sichuan Province, China. sungx077@126.com. ^[6]

关键词 ASPSCR1 TFE3-rRCC Angiogenesis Combination therapy ECM Fusion partner Immune checkpoint inhibitor Immune microenvironment Molecular correlates